MedTrace Logo

Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia

NCT03783910 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-12-21

No results posted yet for this study

Summary

The study was performed in participants suffering from fibromyalgia and investigated efficacy after treatment with several doses of GRT9906 versus placebo. Furthermore, it was to be found out if treatment with GRT9906 was safe and well-tolerated.

Conditions

  • Primary Fibromyalgia

Interventions

DRUG

GRT9906

One prolonged-release tablet containing 40 mg of GRT9906

DRUG

Placebo

Placebo matching GRT9906 tablets

Sponsors & Collaborators

  • Grünenthal GmbH

    lead INDUSTRY

Principal Investigators

  • Grünenthal Study Director · Grünenthal GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-19
Primary Completion
2006-10-31
Completion
2006-10-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03783910 on ClinicalTrials.gov